Aptevo Therapeutics
APVO
1 hedge funds and large institutions have $42.1M invested in Aptevo Therapeutics in 2021 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9.93% less ownership
Funds ownership: 65.66% → 55.73% (-9.9%)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $9.23M
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Kennedy Capital Management
St Louis,
Missouri
|
-$4.22M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.12M |
| 3 |
Anson Funds Management
Dallas,
Texas
|
-$798K |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
-$404K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
-$336K |
APVO Hedge Fund Activity: Q3 2021 in Review
1 of the 5,731 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q3 2021, worth a combined $42.1M — down 36% from $65.5M a quarter earlier.
Fund positioning in APVO was balanced in Q3 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Kennedy Capital Management, cutting an estimated $4.22M.
- 1 institutional investor held Aptevo Therapeutics (APVO) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $42.1M of Aptevo Therapeutics stock for Q3 2021, down 36% quarter-over-quarter.
- 0 funds opened new Aptevo Therapeutics positions in Q3 2021 and 0 closed out.
- The largest Aptevo Therapeutics seller in Q3 2021 was Kennedy Capital Management, an estimated $4.22M sold.
Based on aggregated 13F filings for Q3 2021.